GR3033450T3 - Hypolipidemic benzothiazepines - Google Patents
Hypolipidemic benzothiazepinesInfo
- Publication number
- GR3033450T3 GR3033450T3 GR20000401138T GR20000401138T GR3033450T3 GR 3033450 T3 GR3033450 T3 GR 3033450T3 GR 20000401138 T GR20000401138 T GR 20000401138T GR 20000401138 T GR20000401138 T GR 20000401138T GR 3033450 T3 GR3033450 T3 GR 3033450T3
- Authority
- GR
- Greece
- Prior art keywords
- pct
- date
- hypolipidemic
- benzothiazepines
- sec
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9423172A GB9423172D0 (en) | 1994-11-17 | 1994-11-17 | Hypolipidemic benzothiazepines |
| PCT/GB1995/002700 WO1996016051A1 (en) | 1994-11-17 | 1995-11-16 | Hypolipidemic benzothiazepines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3033450T3 true GR3033450T3 (en) | 2000-09-29 |
Family
ID=10764525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20000401138T GR3033450T3 (en) | 1994-11-17 | 2000-05-19 | Hypolipidemic benzothiazepines |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5998400A (el) |
| EP (1) | EP0792268B1 (el) |
| JP (1) | JP2868623B2 (el) |
| KR (1) | KR970707111A (el) |
| CN (1) | CN1059674C (el) |
| AT (1) | ATE189891T1 (el) |
| AU (1) | AU706325B2 (el) |
| BR (1) | BR9509683A (el) |
| CZ (1) | CZ147397A3 (el) |
| DE (1) | DE69515183T2 (el) |
| DK (1) | DK0792268T3 (el) |
| ES (1) | ES2144151T3 (el) |
| FI (1) | FI972085L (el) |
| GB (1) | GB9423172D0 (el) |
| GR (1) | GR3033450T3 (el) |
| HU (1) | HUT77412A (el) |
| MX (1) | MX9703546A (el) |
| NO (1) | NO308470B1 (el) |
| NZ (1) | NZ295426A (el) |
| PL (1) | PL320093A1 (el) |
| PT (1) | PT792268E (el) |
| WO (1) | WO1996016051A1 (el) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA956647B (en) * | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6107494A (en) * | 1994-09-13 | 2000-08-22 | G.D. Searle And Company | Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6268392B1 (en) | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US6190513B1 (en) | 1997-05-14 | 2001-02-20 | Applied Materials, Inc. | Darkspace shield for improved RF transmission in inductively coupled plasma sources for sputter deposition |
| GB9704208D0 (en) * | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
| GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| AU2157400A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
| US6489366B1 (en) | 1998-12-23 | 2002-12-03 | G. D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| EP1340510A1 (en) | 1998-12-23 | 2003-09-03 | G.D. Searle LLC. | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
| JP2002533414A (ja) | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ |
| JP2002533410A (ja) | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するためのコレステリルエステル転送タンパク質阻害剤およびフィブリン酸誘導体の組み合わせ |
| CN1342090A (zh) | 1998-12-23 | 2002-03-27 | G·D·瑟尔有限公司 | 适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合 |
| PL348508A1 (en) | 1998-12-23 | 2002-05-20 | Searle Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| CA2362147A1 (en) * | 1999-02-12 | 2000-08-17 | Steve A. Kolodziej | 1,2-benzothiazepines for the treatment of hyperlipidemic diseases |
| DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| SE0000772D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| WO2001068637A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
| US20020183307A1 (en) * | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) * | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| TWI331143B (en) | 2001-09-08 | 2010-10-01 | Astrazeneca Uk Ltd | Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them |
| BR0306643A (pt) | 2002-01-17 | 2004-10-19 | Pharmacia Corp | Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| WO2004009093A1 (de) * | 2002-07-23 | 2004-01-29 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterinsenkendes mittel aus ballaststoffen und cholesterinsenkenden stoffen |
| US20040147774A1 (en) * | 2002-12-20 | 2004-07-29 | Aventis Pharma S.A. | Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid |
| DE10261061A1 (de) * | 2002-12-24 | 2004-07-15 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit |
| DE10261067A1 (de) * | 2002-12-24 | 2004-08-05 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| EP1775283A4 (en) * | 2004-07-14 | 2008-12-10 | Japan Tobacco Inc | 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1) |
| KR101042490B1 (ko) * | 2004-07-15 | 2011-06-16 | 니뽄 다바코 산교 가부시키가이샤 | 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제 |
| US7906508B2 (en) * | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
| CA2744817C (en) * | 2008-11-26 | 2020-07-07 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| PL3400944T3 (pl) | 2010-11-04 | 2020-11-16 | Albireo Ab | Inhibitory ibat w leczeniu chorób wątroby |
| JP6097695B2 (ja) | 2010-11-08 | 2017-03-15 | アルビレオ アクチエボラグ | Ｉｂａｔ阻害剤および胆汁酸結合剤を含む薬学的組み合わせ |
| CN104023727B (zh) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂 |
| CA2852957C (en) | 2011-10-28 | 2020-08-04 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| US20140275090A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| CN105228615A (zh) | 2013-03-15 | 2016-01-06 | 鲁美纳医药公司 | 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂 |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| EP3413877B1 (en) | 2016-02-09 | 2021-04-07 | Albireo AB | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| KR101844184B1 (ko) | 2017-07-21 | 2018-04-02 | 씨제이헬스케어 주식회사 | 아미노알킬벤조티아제핀 유도체의 용도 |
| JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
| CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES2942443T3 (es) | 2018-06-05 | 2023-06-01 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| BR112020024479A2 (pt) | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| HUE060905T2 (hu) | 2019-02-06 | 2023-04-28 | Albireo Ab | Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| ES2955799T3 (es) * | 2019-02-06 | 2023-12-07 | Albireo Ab | Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares |
| PL3923943T3 (pl) | 2019-02-12 | 2024-12-09 | Mirum Pharmaceuticals, Inc. | Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych |
| AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
| CA3158181A1 (en) * | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TWI877263B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| TWI867107B (zh) | 2019-12-04 | 2024-12-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
| CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| ES2973549T3 (es) | 2019-12-04 | 2024-06-20 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares |
| TWI877262B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其作為膽酸調節劑之用途 |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| KR20250022025A (ko) | 2022-06-09 | 2025-02-14 | 알비레오 에이비 | 간염 치료 |
| CN119487013A (zh) | 2022-07-05 | 2025-02-18 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| AU2023390975A1 (en) | 2022-12-09 | 2025-06-05 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59231018A (ja) * | 1983-06-10 | 1984-12-25 | Tanabe Seiyaku Co Ltd | 抗脂血剤 |
| US4902684A (en) | 1988-06-20 | 1990-02-20 | E. R. Squibb & Sons, Inc. | Benzazepine and benzothiazepine derivatives |
| DE69015682T2 (de) * | 1989-04-28 | 1995-05-11 | Tanabe Seiyaku Co | Verfahren zur Herstellung von 1,5-Benzothiazepinderivaten. |
| GB2255937B (en) * | 1991-05-21 | 1994-11-09 | Andrew Thomas Kinnaird | Sailboards |
| GB9111376D0 (en) * | 1991-05-25 | 1991-07-17 | Boots Co Plc | Therapeutic agents |
| GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| JPH08505374A (ja) * | 1992-12-11 | 1996-06-11 | チバ−ガイギー アクチェンゲゼルシャフト | ベンズアゼピノン誘導体 |
| IL108633A (en) * | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
| IL108634A0 (en) * | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| GB9307017D0 (en) * | 1993-04-02 | 1993-05-26 | Bp Chem Int Ltd | Control of ammonia emission and odour |
| WO1995004534A1 (en) * | 1993-08-06 | 1995-02-16 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| ZA956647B (en) * | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| GB9704208D0 (en) * | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
-
1994
- 1994-11-17 GB GB9423172A patent/GB9423172D0/en active Pending
-
1995
- 1995-11-16 NZ NZ295426A patent/NZ295426A/en unknown
- 1995-11-16 BR BR9509683A patent/BR9509683A/pt not_active IP Right Cessation
- 1995-11-16 ES ES95937940T patent/ES2144151T3/es not_active Expired - Lifetime
- 1995-11-16 CZ CZ971473A patent/CZ147397A3/cs unknown
- 1995-11-16 DE DE69515183T patent/DE69515183T2/de not_active Expired - Fee Related
- 1995-11-16 CN CN95196304A patent/CN1059674C/zh not_active Expired - Fee Related
- 1995-11-16 FI FI972085A patent/FI972085L/fi unknown
- 1995-11-16 US US08/836,405 patent/US5998400A/en not_active Expired - Fee Related
- 1995-11-16 MX MX9703546A patent/MX9703546A/es not_active IP Right Cessation
- 1995-11-16 AU AU38762/95A patent/AU706325B2/en not_active Ceased
- 1995-11-16 WO PCT/GB1995/002700 patent/WO1996016051A1/en not_active Ceased
- 1995-11-16 JP JP51666196A patent/JP2868623B2/ja not_active Expired - Fee Related
- 1995-11-16 AT AT95937940T patent/ATE189891T1/de not_active IP Right Cessation
- 1995-11-16 PL PL95320093A patent/PL320093A1/xx unknown
- 1995-11-16 DK DK95937940T patent/DK0792268T3/da active
- 1995-11-16 HU HU9702189A patent/HUT77412A/hu unknown
- 1995-11-16 EP EP95937940A patent/EP0792268B1/en not_active Expired - Lifetime
- 1995-11-16 PT PT95937940T patent/PT792268E/pt unknown
-
1997
- 1997-05-16 KR KR1019970703298A patent/KR970707111A/ko not_active Withdrawn
- 1997-05-16 NO NO972261A patent/NO308470B1/no unknown
-
2000
- 2000-05-19 GR GR20000401138T patent/GR3033450T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ147397A3 (en) | 1997-11-12 |
| WO1996016051A1 (en) | 1996-05-30 |
| JP2868623B2 (ja) | 1999-03-10 |
| KR970707111A (ko) | 1997-12-01 |
| DK0792268T3 (da) | 2000-07-31 |
| NO972261D0 (no) | 1997-05-16 |
| NZ295426A (en) | 1997-10-24 |
| DE69515183D1 (de) | 2000-03-30 |
| PT792268E (pt) | 2000-06-30 |
| PL320093A1 (en) | 1997-09-15 |
| NO972261L (no) | 1997-07-16 |
| CN1164230A (zh) | 1997-11-05 |
| FI972085A7 (fi) | 1997-05-15 |
| FI972085A0 (fi) | 1997-05-15 |
| BR9509683A (pt) | 1997-09-16 |
| EP0792268B1 (en) | 2000-02-23 |
| DE69515183T2 (de) | 2000-08-17 |
| HUT77412A (hu) | 1998-04-28 |
| AU706325B2 (en) | 1999-06-17 |
| JPH11500102A (ja) | 1999-01-06 |
| ATE189891T1 (de) | 2000-03-15 |
| EP0792268A1 (en) | 1997-09-03 |
| AU3876295A (en) | 1996-06-17 |
| MX9703546A (es) | 1997-08-30 |
| US5998400A (en) | 1999-12-07 |
| FI972085L (fi) | 1997-05-15 |
| GB9423172D0 (en) | 1995-01-04 |
| ES2144151T3 (es) | 2000-06-01 |
| CN1059674C (zh) | 2000-12-20 |
| NO308470B1 (no) | 2000-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9423172D0 (en) | Hypolipidemic benzothiazepines | |
| TR200001816T2 (tr) | Hipolipidemik benzotiyazepin bileşikleri | |
| DE69522947D1 (en) | Phenylxanthin-derivate | |
| HUT72436A (en) | Process for the production of imidazopyridines and pharmaceutical compositions containing them and which are suitable for treating gastro-intestinal diseases | |
| DE69514813D1 (en) | Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren | |
| ZA953469B (en) | New compound | |
| LU91145I9 (el) | ||
| TW274547B (el) | ||
| DE69520364D1 (de) | Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate-aufnahme | |
| WO2000047568A3 (en) | 1,2-benzothiazepines for the treatment of hyperlipidemic diseases | |
| IL79379A0 (en) | Carboxylic acid derivatives,process for the preparation thereof and pharmaceutical compositions containing them | |
| HU9403690D0 (en) | Branched-amino-substituted thiazoles, process for their preparation and the pharmaceutical compositions which contan them | |
| IL124966A0 (en) | 1-indanyl- and 1-indanylidene-acetic derivatives | |
| PL328225A1 (en) | Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors | |
| HU9303082D0 (en) | Process for production of 3,4-dihydro-2(1h)-quinolyne-derivatives with neuroprotective action and of pharmaceutical compositions containing them as medical agent | |
| NZ320522A (en) | Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds | |
| IL88726A0 (en) | Dihydrothienobenzodiazepinone derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof | |
| GR3025050T3 (en) | Etoposide derivatives, process for their preparation, their use as a drug and in the preparation of a drug for treating cancer. | |
| IL117083A (en) | Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical compositions containing these compounds | |
| BR0010338A (pt) | Composto enanciomericamente enriquecido, composição farmacêutica, método para tratar uma doença ou condição mediada por cck-a, uso de um composto, e, processo para a preparação de um composto | |
| DE69109293D1 (de) | Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |